These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23723112)

  • 21. Treatment of osteoporosis in women intolerant of oral bisphosphonates.
    Aspray TJ; Francis RM
    Maturitas; 2012 Jan; 71(1):76-8. PubMed ID: 22079368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Bone micro-structural changes following osteoporotic drug treatment].
    Mori S
    Clin Calcium; 2013 Jul; 23(7):1027-33. PubMed ID: 23811592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Newly developed drugs for osteoporosis in overseas and their future roles for the therapy].
    Wada S; Fukawa T; Kamiya S
    Clin Calcium; 2008 Oct; 18(10):1483-92. PubMed ID: 18830046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab for the prevention of osteoporotic fractures in postmenopausal women.
    Waugh N; Royle P; Scotland G; Henderson R; Hollick R; McNamee P
    Health Technol Assess; 2011 May; 15 Suppl 1():51-9. PubMed ID: 21609653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2012 Mar; 22(3):315-20. PubMed ID: 22370297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
    Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
    Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.
    Gasser JA
    Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Medical treatment of osteoporosis in men].
    Eiken PA; Vestergaard P
    Ugeskr Laeger; 2015 Aug; 177(36):. PubMed ID: 26324291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of osteoporosis in octogenarians].
    Pepersack T
    Rev Med Brux; 2008 Sep; 29(4):311-6. PubMed ID: 18949982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone-forming agents in the management of osteoporosis.
    Neuprez A; Reginster JY
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):869-83. PubMed ID: 19028361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E; Lang A; Robbins S; Ström O
    Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.
    Lippuner K; Pollock RF; Smith-Palmer J; Meury T; Valentine WJ
    Appl Health Econ Health Policy; 2011 Nov; 9(6):403-17. PubMed ID: 21910511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Trends in osteoporosis].
    Uebelhart B; Rizzoli R
    Rev Med Suisse; 2008 Jan; 4(140):144-6, 148-9. PubMed ID: 18309878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
    Maugeri D; Russo E; Luca S; Leotta C; Mamazza G; Sorace R; Rizzotto M; Manuele S; Fiore V; Taverna G; Castiglia B; Calitro M
    Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bi-directionally selective bone targeting delivery for anabolic and antiresorptive drugs: a novel combined therapy for osteoporosis?
    Liu J; Zhang H; Dong Y; Jin Y; Hu X; Cai K; Ma J; Wu G
    Med Hypotheses; 2014 Dec; 83(6):694-6. PubMed ID: 25459136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging drugs for osteoporosis.
    Feurer E; Chapurlat R
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):385-95. PubMed ID: 24995794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A guide for osteoporosis management].
    Zárate A; Saucedo R; Basurto L
    Gac Med Mex; 2004; 140(2):235-40. PubMed ID: 15162957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.